Natrium- und Kalziumstoffwechselstörungen in der Notaufnahme

[1]  W. Fenske.  [Hyponatremia in emergency admissions - often dangerous]. , 2017, Der Internist.

[2]  C. Kasperk,et al.  Hyperkalzämische Krise und hypokalzämische Tetanie , 2017, Der Internist.

[3]  H. Sørensen,et al.  Hyponatremia and mortality risk: a Danish cohort study of 279 508 acutely hospitalized patients. , 2015, European journal of endocrinology.

[4]  C. Marcocci,et al.  Epidemiology, pathogenesis of primary hyperparathyroidism: Current data. , 2015, Annales d'endocrinologie.

[5]  Devin W. Steenkamp,et al.  Hypercalcemic crisis: a clinical review. , 2015, The American journal of medicine.

[6]  D. Annane,et al.  Clinical practice guideline on diagnosis and treatment of hyponatraemia. , 2014, European journal of endocrinology.

[7]  E. Berber,et al.  The prevalence of undiagnosed and unrecognized primary hyperparathyroidism: a population-based analysis from the electronic medical record. , 2013, Surgery.

[8]  J. Verbalis,et al.  Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. , 2013, The American journal of medicine.

[9]  L. Rejnmark,et al.  Hypoparathyroidism in the adult: Epidemiology, diagnosis, pathophysiology, target‐organ involvement, treatment, and challenges for future research , 2011, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[10]  T. Berl,et al.  Efficacy and safety of oral tolvaptan therapy in patients with the syndrome of inappropriate antidiuretic hormone secretion. , 2011, European journal of endocrinology.

[11]  T. Berl,et al.  Oral tolvaptan is safe and effective in chronic hyponatremia. , 2010, Journal of the American Society of Nephrology : JASN.

[12]  D. Shoback.  Clinical practice. Hypoparathyroidism. , 2008, The New England journal of medicine.

[13]  R. Phitayakorn,et al.  Hyperparathyroid crisis: use of bisphosphonates as a bridge to parathyroidectomy. , 2008, Journal of the American College of Surgeons.

[14]  T. Berl,et al.  Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. , 2006, The New England journal of medicine.

[15]  D. Thiebaud,et al.  Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): Respective role of kidney and bone , 1990, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.